Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion ...

While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Right now, Lilly trades at a forward price to earnings (P/E) multiple of 36. As the chart below illustrates, Lilly's current forward P/E is roughly 40% lower today than it was just a year ago.